Excelsior Biopharma Inc AI Stock Analysis
Excelsior Biopharma Inc (6496) AI Stock Analysis
Excelsior Biopharma Inc
(TPEx:6496)
The score is driven primarily by deteriorating financials: record operating and net losses, deeply negative return on equity, and three consecutive years of operating cash burn that is draining a shrinking equity base while leverage rises. Improving gross margins and renewed revenue growth are genuine positives, but they have not translated into profitability. Technicals reinforce the caution, with the price below all key moving averages and negative MACD momentum. Valuation provides no cushion given negative earnings and the absence of a dividend. Until operating losses narrow and cash burn reverses, risk remains elevated.
Excelsior Biopharma Inc (6496) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.05B
- Dividend Yield
- ―
- Average Volume (3M)
- 21.20K
- Price to Earnings (P/E)
- -5.9
- Beta (1Y)
- 0.13
- Revenue Growth
- 11.64%
- EPS Growth
- -10.83%
- Country
- TW
- Employees
- 15
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Excelsior Biopharma Inc Business Overview & Revenue Model
Company Description
Excelsior Biopharma Inc., established in 1988 and headquartered in Taipei, Taiwan, functions as a pharmaceutical enterprise with a global market presence, encompassing Taiwan, China, and other international regions. The company offers a comprehensive...
Excelsior Biopharma Inc Financial Statement Overview
Summary
Financials are weak across all three statements. Revenue is recovering (NT$898M, +4%) and gross margin has roughly doubled since 2020 to about 40%, but operating and net losses widened to record levels (-NT$174M operating, -NT$183M net, -20% net margin) with negative EBITDA. The balance sheet is still solvent — equity of NT$804M exceeds debt of NT$533M — but equity has eroded by over a third since 2020 while debt rose, lifting debt-to-equity from 0.31 to 0.66, and ROE is roughly -23%. Cash flow is the weakest element: a third straight year of operating cash burn (-NT$139M) and negative free cash flow (-NT$176M), with burn exceeding the reported loss. Reduced capital spending offers modest relief, but the company remains dependent on external funding.
Income Statement
27NegativeBalance Sheet
44NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 936.92M | 898.26M | 861.91M | 771.56M | 671.76M | 1.34B |
| Gross Profit | 328.29M | 360.17M | 382.10M | 306.93M | 287.17M | 293.35M |
| EBITDA | -128.44M | -92.90M | -8.40M | -29.37M | 4.41M | 23.16M |
| Net Income | -206.58M | -183.17M | -98.70M | -91.01M | -33.76M | -15.65M |
Balance Sheet | ||||||
| Total Assets | 1.42B | 1.48B | 1.58B | 1.58B | 1.71B | 1.84B |
| Cash, Cash Equivalents and Short-Term Investments | 141.10M | 185.34M | 251.53M | 589.92M | 1.11B | 1.10B |
| Total Debt | 524.98M | 533.46M | 438.49M | 377.40M | 375.83M | 397.19M |
| Total Liabilities | 728.80M | 679.78M | 586.89M | 472.87M | 507.53M | 608.90M |
| Stockholders Equity | 688.99M | 804.23M | 991.45M | 1.10B | 1.21B | 1.23B |
Cash Flow | ||||||
| Free Cash Flow | -162.02M | -175.67M | -356.95M | -170.41M | -2.30M | 52.95M |
| Operating Cash Flow | -147.42M | -138.72M | -99.80M | -134.75M | 5.49M | 55.82M |
| Investing Cash Flow | 238.00K | -24.40M | -307.03M | 146.62M | -199.24M | -10.68M |
| Financing Cash Flow | 147.97M | 108.38M | 56.99M | -317.23M | -13.73M | -83.04M |
Excelsior Biopharma Inc Peers Comparison
Overall Rating
- TW:649633Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6496 | 33Underperform | TWD 1.13B | -5.88 | ― | ― | 11.64% | -10.83% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6496 | Excelsior Biopharma Inc | 23.65 | -5.40 | -18.59% | |
| TW:4172 | InnoPharmax, Inc. | 9.42 | -7.67 | -44.86% | |
| TW:6483 | Original Biomedicals Co Ltd | 14.80 | 4.85 | 48.74% | |
| TW:6676 | Sunny Pharmtech Inc. | 7.12 | -7.03 | -49.68% | |
| TW:6677 | Anxo Pharmaceutical Co., Ltd. | 20.95 | -3.15 | -13.07% | |
| TW:6810 | Bio Preventive Medicine Corp. | 22.75 | -1.75 | -7.14% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026